Clinical Trials Logo

Hepatocellular Carcinoma clinical trials

View clinical trials related to Hepatocellular Carcinoma.

Filter by:

NCT ID: NCT04264754 Terminated - Clinical trials for Hepatocellular Carcinoma

Characterization of Methylation Patterns in Hepatocellular Carcinoma

Start date: February 13, 2018
Phase:
Study type: Observational

This study is being performed as part of the development process of the Liver EpiCheck test which includes the identification of different methylation profiles in HCC (hepatocellular carcinoma) patients compare to cancer free control in blood samples

NCT ID: NCT04244552 Terminated - Breast Cancer Clinical Trials

A Phase 1b Trial of ATRC-101 in Adults With Advanced Solid Malignancies

Start date: February 11, 2020
Phase: Phase 1
Study type: Interventional

ATRC-101-A01 is a Phase 1b, open-label dose escalation and expansion trial of ATRC-101, an engineered fully human immunoglobulin G, subclass 1 (IgG1) antibody derived from a naturally occurring human antibody. The safety, tolerability, PK, and biological activity of ATRC-101 will be characterized when administered every two weeks (Q2W) or every 3 weeks (Q3W) as a monotherapy or in combination with other anticancer agents.

NCT ID: NCT04187872 Terminated - Clinical trials for Hepatocellular Carcinoma

LITT and Pembrolizumab in Recurrent Brain Metastasis

TORCH
Start date: January 10, 2020
Phase: Phase 1
Study type: Interventional

This is an open-label, historically controlled pilot study investigating the immune effect of Laser Interstitial ThermotHerapy (LITT)+ pembrolizumab in adult patients with a primary cancer approved by the FDA for treatment with an immune-checkpoint inhibitor who have recurrent brain metastasis after prior stereotactic radiosurgery (SRS).

NCT ID: NCT04150874 Terminated - Clinical trials for Hepatocellular Carcinoma

Contrast-Enhanced Ultrasound for the Evaluation of Changes in Tumor Blood Flow Surrounding HAE

Start date: February 19, 2020
Phase: Early Phase 1
Study type: Interventional

The purpose of the study is to find out if a study agent called Lumason® microbubbles may be helpful for people with lesions in the liver. It is possible it may help determine an early response to radioembolization and/or help demonstrate radiation toxicity to the surrounding liver.

NCT ID: NCT04106167 Terminated - Colorectal Cancer Clinical Trials

Long-term, Non-interventional, Observational Study Following Treatment With Fate Therapeutics FT500 Cellular Immunotherapy

Start date: June 11, 2019
Phase:
Study type: Observational

Subjects who previously took part in the FT500-101 study and received allogeneic NK cell immunotherapy will take part in this long term follow-up study. Subjects will automatically enroll into study FT-003 once they have withdrawn or complete the parent interventional study. The purpose of this study is to provide long-term safety and survival data for subjects who have participated in the parent study. No additional study drug will be given, but subjects can receive other therapies for their cancer while they are being followed for long term safety in this study.

NCT ID: NCT04099277 Terminated - Clinical trials for Hepatocellular Carcinoma

A Study of LY3435151 in Participants With Solid Tumors

Start date: October 28, 2019
Phase: Phase 1
Study type: Interventional

The reason for this study is to see if the study drug LY3435151 is safe in participants with advanced solid tumors.

NCT ID: NCT04077372 Terminated - Colorectal Cancer Clinical Trials

Assessment of a Serious Illness Conversation Guide (SICG) in Advanced Gastro-Intestinal Cancers

Start date: September 16, 2019
Phase: N/A
Study type: Interventional

The purpose of the study is to determine whether standardized implementation of a scripted template for discussing important issues that arise near the end of life improves the care of those who have advanced cancer.

NCT ID: NCT04060342 Terminated - Clinical trials for Non-small Cell Lung Cancer

GB1275 Monotherapy and in Combination With an Anti-PD1 Antibody in Patients With Specified Advanced Solid Tumors or in Combination With Standard of Care in Patients With Metastatic Pancreatic Adenocarcinoma

Start date: August 13, 2019
Phase: Phase 1
Study type: Interventional

This first-in-human (FIH ) study is an open-label, multicenter study that consists of a Phase 1 Dose Escalation/Expansion phase of GB1275 monotherapy or in combination with Anti-PD-1 Antibody or in combination with Standard of Care in Patients with Metastatic Pancreatic Adenocarcinoma followed by a Phase 2 Basket Expansion phase in Patients with Specified Metastatic Solid Tumors

NCT ID: NCT03998033 Terminated - Clinical trials for Hepatocellular Carcinoma

Study of ET140202 T Cells in Adults With Advanced Hepatocellular Carcinoma

ET-109
Start date: May 30, 2019
Phase: Phase 1
Study type: Interventional

This is a open-label, dose escalation, multi-center, Phase I / Phase II study to assess the safety of an autologous T-cell product (ET140202) in adult subjects with advanced Alpha-fetoprotein (AFP) positive/Human Leukocyte Antigen (HLA) A-2 positive Hepatocellular Carcinoma (HCC).

NCT ID: NCT03979547 Terminated - Clinical trials for Hepatocellular Carcinoma

EXALT: EXercise Attenuates Liver Tumors Trial

EXALT
Start date: January 3, 2019
Phase: N/A
Study type: Interventional

The overall goal of this proposal is to test the effect of exercise to delay or avert HCC recurrence and gain information regarding the potential molecular mechanisms of HCC tumor inhibition by exercise.